BioSpace

T-time: British biotech pours $133M into the pot for bispecifics

With backing from three Big Pharma investment arms, British biotech T-Therapeutics is brewing up a clinical launch for its cancer and autoimmune T cell engagers.

By BioSpace

1 min read
T-time: British biotech pours $133M into the pot for bispecifics
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights